We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
14/7/2015 11:05 | For you Tulip............. | mike740 | |
14/7/2015 09:18 | Just had a good look at this one. Those last results well, were to say at the very best just wishful thinking. Sounds all round like a duff entry to 'Dragons Den' wouldnt even get an invite to the show. With that in mind I wouldnt touch these with a barge pole. | mike740 | |
14/7/2015 08:20 | RNS Number : 9186S Collagen Solutions PLC 14 July 2015 Collagen Solutions Plc (the "Company" or the "Group") Partnership with UCL and Oxford MEStar Ltd in grant funded project Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it is part of a consortium that has been awarded an Arthritis Research UK (ARUK) Point of Care grant to develop novel functionally man-made osteochondral scaffold for large osteochondral defect repairs. Osteochondral injury refers to repetitive trauma within a joint such as the knee or elbow. Collagen will collaborate with UCL and Oxford MEStar, a rapidly growing company specialising in translational and regenerative medicine. Successful delivery of this programme will lead to the development of a novel scaffold that can be used clinically in a one-step surgical procedure for treatment of large osteochondral defects. As a result, the quality of life of individuals with these defects, which often lead to osteoarthritis, will be improved allowing a pain free, more active lifestyle. Stewart White, CEO of Collagen Solutions commented: "Our relationship with UCL has already led to the licensing of novel collagen material from the laboratories of Professor Brown. This new grant widens our collaboration with the University and will lead to the development of another collagen based, high value added product which fits in with our strategy of releasing the embedded functionality of our medical grade collagen through the development and commercialization of high value added novel products." | doodlebug4 | |
13/7/2015 08:18 | The market seems to approve of the Final Results. Small steps in the right direction. | doodlebug4 | |
22/6/2015 08:16 | Collagen Solutions PLC Innovate UK Grant Award Alert TIDMCOS Collagen Solutions PLC 22 June 2015 Collagen Solutions Plc (the "Company" or the "Group") Innovate UK Grant Award for partnership with Electrospinning Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to announce a grant award from Innovate UK's Technology Strategy Board. The Electrospinning Company Ltd ('Electrospinning') in partnership with the Company have won an Inspired Feasibility Competition to develop a novel bio-synthetic substance for use in internal wound healing. The Company will provide the raw materials needed to develop a novel bio-synthetic substance for use in internal wound healing. In addition Collagen and Electrospinning will combine their expertise in synthetic and biological materials to develop the material that combines the advantages of synthetic polymers such as flexibility, strength and consistency, with the bio-performance advantages of collagen, such as providing cell recognition sites for cell adhesion, proliferation and ultimately improved tissue regeneration at wound sites. Stewart White, CEO of Collagen Solutions plc said: "We are delighted to have been chosen by The Electrospinning Company for this project. The global market for surgical meshes, for example for hernia repair, is over $1 billion (Frost & Sullivan) growing at over 6% CAGR (Transparency market research 2013), driven by increasing obesity and aging populations. Yet despite being a well-established market there remain unmet needs and attractive opportunities for advanced mesh materials which promote rapid healing and reduce the risk of rejection and infection." | doodlebug4 | |
12/6/2015 07:27 | Bet me to it ts ;-) | jacobjohn7 | |
28/4/2015 09:21 | Buy rating from panmure though. Lowered exposure but opted for worry free amount. . Analyst rating have uncanny knack of boosting to the suggested level. Keep rest of powder dry for now | jacobjohn7 | |
27/4/2015 15:37 | Guess they are no better or worse than a lot of companies, but the phrase 'surprise to the upside' is a damn hard one for a lot of companies to master! COS do look an interesting proposition, but like you, will watch from sidelines for now. | the prophet | |
27/4/2015 15:34 | Well im watching from sidelines now... company being abit deceitful which doesnt bode well. Will watch for re entry point. | jacobjohn7 | |
21/4/2015 07:28 | well, COS is about to slip off my radar, least for a year or two! That note is damn cheeky and takes the biscuit! | the prophet | |
20/4/2015 15:54 | Yes- good point Prophet. 'Slippage'- lovely word; even better 'just slippage'- lovely phrase. Almost not worth mentioning and I would have left this subject if Hardman authors weren't so dismissive of it. The actualite is the company got it wrong blaming about half a dozen different causes not within their control. Well enough said. They better not get it wrong next time. But if you cannot predict within +/- 30% in a couple of months (investors presentation onwards) then what hope is there for getting the forward yearly forecasts right. Taking a football metaphor they need to get something in the back of the net next time- not an own goal. | totaleclipse | |
20/4/2015 10:22 | notes here yes, the usual dcf valuation! gawd knows how brokers would be able to pin a 'decent' valuation on companies without it! What I don't quite get,if the short-fall in sales from year 14/15 are not lost, but,as the note says, just slippage, one would expect an up-graded 15/16? But no, in their new forecasts,, instead of adding on £360K 'slipped' revenue, they lop £600K off forecasts and just for good measure add £0.2m admin costs and £0.1m sales and marketing costs! Nice one! Effectively this note is a down-grade. eps is forecast to be: 15/16 minus 0.42p 16/17 0.52p 17/18 1.43p So at current share price of 11.375p shares are on a year forward p/e of 22 one year out dropping to 8 two year out. With the execution risk, that looks high enough for now, one to keep on the watch list and see if they can deliver? | the prophet | |
20/4/2015 08:57 | Cheers, totaleclipse.will have to read note and the basis for 32p.If it's derived from the oft used discounted cash flow basis, that is more or less the same as plucking a number out of thin air! | the prophet | |
20/4/2015 08:21 | Well my expectation of an announcement comes in the form of a new analysis from Hardman & Co describing the recent shortfall in sales as 'disappointing but hardly a disaster'. They value the company at 32p a share. We'll see | totaleclipse | |
11/3/2015 18:56 | Pretty bad form re : pi's. But have to see it as an interesting company.chairman does own 7% of company. He is privy to info so expects to make money. | jacobjohn7 | |
11/3/2015 13:34 | Good points Prophet. Enough from me on this for now- I expect them to issue all sorts of little positive notices over the next 1-2 months on customer interactions to allay concerns but we now know that it's the sales that count- the ACTUAL, cash in the till, sales. As you so wisely say- they need to under promise and over deliver. | totaleclipse | |
11/3/2015 10:12 | ps, still, least someone like COS, 100,000 buy, director perchance? | the prophet | |
11/3/2015 09:52 | And what's all this 'market consensus 1.358 million all about. Figures in the presentation were over £1.4 million. So 40% adrift after 5 weeks- shocking! I, for one, will not spend the time and effort of getting to London for a free sarney and G&T only to be told a load of old baloney. I agree with prophet's point that an investor teach-in is going to be translated as a future profit warning | totaleclipse | |
11/3/2015 09:34 | ps meeting was actually 3rd February, so 5 weeks from that to warning! Bloody brilliant! | the prophet |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions